Clinical Trial Update: A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia [Phase 3]

View source ↗

Summary

Phase 3, 52-week study of bococizumab in subjects with heterozygous familial hypercholesterolemia completed; results were posted in May 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heterozygous Familial Hypercholesterolemia

Drugs mentioned

• Bococizumab (bococizumab)

Snippet

Sponsor: Pfizer | Conditions: Heterozygous Familial Hypercholesterolemia | Phase 3 | Status: COMPLETED | Results posted: 2017-05-19